Novartis chief Vasella bows out with mea culpa
The outgoing chairman of the Basel-based pharmaceuticals giant Novartis acknowledged Friday that he had made "mistakes" in connection with a scandal over a massive golden handshake he finally agreed to forego.
"I have committed two mistakes that could have been avoided," Daniel Vasella told the Novartis general assembly on his last day on the job.
The first, he said, had been to accept a goodbye package of a whopping 72 million francs ($77 million), meant to ensure that he doesn't go work for any Novartis rivals.
The second, he added, had been to think he could calm the public outrage by announcing last Tuesday he would forgo the golden handshake, which he insisted had intended to give to charity.
The sum caused an outcry among politicians across Switzerland's spectrum, while the tabloid Blick summed it up as "insane", and transparency campaigners pushing for more shareholders' rights filed a lawsuit.
"I know that for the board, I have not always been an easy partner," Vasella told the room full of shareholders.
But I am responsible and I accept the criticism."
The value of the 59-year-old's golden handshake was revealed last week by the blog Inside Paradeplatz, named after Zurich's financial district.
Novartis finally back-pedalled, announcing on Tuesday that the deal, worth 12 million francs over the coming six years, had been cancelled.
Ulrich Lehner, vice-president of the Novartis board, on Friday lauded Vasella, who has headed the company for 17 years.
"Out of two medium-sized companies in Basel, Mr. Vasella built a group with a global name," Lehner told shareholders.
Novartis was born from a 1996 merger between the Ciba-Geigy and Sandoz laboratories, both based in Basel on Switzerland's border with Germany and France.
Novartis posted a net profit of $9.6 billion in 2012, up four percent from the previous year, though sales were down three percent to $56.5 billion amid competition from generic drugs.
Despite being hailed by Lehner for his track record, Vasella came under fire from angry shareholders.
"If you'd thought before accepting 72 million, you'd have avoided damaging Novartis' image.," said Rudolf Meyer, head of Actares, a sustainable business group that holds stock
in the company.
"You and the board have failed to act transparently,"
The announcement of the golden handshake came ahead of a March 3rd referendum — the bedrock of Switzerland's direct democracy — in which voters will decide whether to give shareholders more powers to rein in executive pay.
Polls show that a clear majority is set to back the measures.
Comments
See Also
"I have committed two mistakes that could have been avoided," Daniel Vasella told the Novartis general assembly on his last day on the job.
The first, he said, had been to accept a goodbye package of a whopping 72 million francs ($77 million), meant to ensure that he doesn't go work for any Novartis rivals.
The second, he added, had been to think he could calm the public outrage by announcing last Tuesday he would forgo the golden handshake, which he insisted had intended to give to charity.
The sum caused an outcry among politicians across Switzerland's spectrum, while the tabloid Blick summed it up as "insane", and transparency campaigners pushing for more shareholders' rights filed a lawsuit.
"I know that for the board, I have not always been an easy partner," Vasella told the room full of shareholders.
But I am responsible and I accept the criticism."
The value of the 59-year-old's golden handshake was revealed last week by the blog Inside Paradeplatz, named after Zurich's financial district.
Novartis finally back-pedalled, announcing on Tuesday that the deal, worth 12 million francs over the coming six years, had been cancelled.
Ulrich Lehner, vice-president of the Novartis board, on Friday lauded Vasella, who has headed the company for 17 years.
"Out of two medium-sized companies in Basel, Mr. Vasella built a group with a global name," Lehner told shareholders.
Novartis was born from a 1996 merger between the Ciba-Geigy and Sandoz laboratories, both based in Basel on Switzerland's border with Germany and France.
Novartis posted a net profit of $9.6 billion in 2012, up four percent from the previous year, though sales were down three percent to $56.5 billion amid competition from generic drugs.
Despite being hailed by Lehner for his track record, Vasella came under fire from angry shareholders.
"If you'd thought before accepting 72 million, you'd have avoided damaging Novartis' image.," said Rudolf Meyer, head of Actares, a sustainable business group that holds stock
in the company.
"You and the board have failed to act transparently,"
The announcement of the golden handshake came ahead of a March 3rd referendum — the bedrock of Switzerland's direct democracy — in which voters will decide whether to give shareholders more powers to rein in executive pay.
Polls show that a clear majority is set to back the measures.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.